A clinical trial to reduce the treatment time for the Buruli ulcer by half
- Regional Country
- 1.860.033 € Investment
- 2020-25 Length
The Challenge
The Buruli ulcer affects thousands of people in 33 countries and causes disability and stigma.
After decades combatting the Buruli ulcer, which affects thousands of people in over 33 countries, we are still unaware of its exact mode of transmission. We know it is related to environments with stagnant and unsafe water.
Luckily, the Buruli ulcer has a cure via a treatment combining antibiotics (rifampicin and clarithromycin) over eight weeks. Although in many endemic countries these antibiotics are free, the economic burden of transport, accommodation and food for patients and their carers, and the loss of income and work is too high for those affected and their families, particularly if they require lengthy hospital stays. These expenses affect the health system and families and communities suffering from the disease.
The solution
Through two international research consortiums in Ivory Coast, Ghana, Togo and Benin, we are designing an effective four-week treatment that could reduce healing times and, therefore, expenses related to hospitalisation, travel and care for people suffering from the Buruli ulcer.
- We have implemented a clinical trial in Ivory Coast, Ghana, Togo and Benin.
- We train health staff in implementing procedures of the clinical trial in four countries and the standardisation of diagnosis and wound treatment.
- We strengthen transnational synergies between organisations that work to research and combat NTDs such as the Buruli ulcer.
The consortiums are made up of the Aragón Foundation for Research and Development (ARAID), the University of Zaragoza, the Carlos III Health Institute (ISCIII) and the Anesvad Foundation, from Spain; the Raoul Follereau Foundation (FRF), from France; and the University of Abomey-Calavi (UAC), from Benin, with the support of the Tres Cantos Open Lab Foundation (TCOLF) and GlaxoSmithKline (GSK).
Impact
A positive result in this clinical trial could change the WHO’s guidelines regarding the Buruli ulcer.
A shorter, highly effective and completely oral treatment would reduce the length of the treatment and the healing time of all number of wounds.
Furthermore, this would have an impact on the expenditure related to hospitalisation and the family costs to support the patient.
The insightful information we will obtain could in turn impact strategies to shorten treatments for other infections caused by micro bacteria such as tuberculosis and leprosy.
Related projects
See other projects where we fight Neglected Tropical Diseases
Strengthening the African network of laboratories for Buruli ulcer research
There are currently no unified protocols for detecting Buruli ulcer. Although the WHO sets guidelines for the control of NTDs, many laboratories in Africa do not have standardised protocols for sample collection and subsequent screening and diagnosis of these diseases.
Simultaneous diagnosis of five skin-related neglected tropical diseases (skin NTDs)
Through this initiative, we are contributing to strengthening public health systems, from small aid stations in the remotest villages to health centres in reference-point towns.
A New Early Detection System for Buruli Ulcer
This will increase early detection, reducing the number of severe cases of the disease, and in turn will lower expenses for patients and their families as there will be fewer severe cases requiring intensive care.
Better Mental Health for People with NTDs in Nigeria as a Result of Integrated Care
This initiative will support the Nigerian government and other civil society organisations to develop and pilot-test a comprehensive intervention to integrate mental health and NTDs.
An Initiative to Find Innovative Interventions for the Comprehensive Treatment of NTDs
These lessons learnt in Liberia can also be applied to other settings in the region, thereby contributing to a regional exchange of scientific knowledge. Finally, the findings could also be adopted into public health policies in Liberia.
Support for Leprosy Research Teams Via the Leprosy Research Initiative (LRI)
These lessons learnt in Liberia can also be applied to other settings in the region, thereby contributing to a regional exchange of scientific knowledge. Finally, the findings could also be adopted into public health policies in Liberia.
Creating Scientific Research Opportunities on NTDs for Young Professionals from Countries Where these Diseases Are Endemic
Encouraging young researchers in countries where skin NTDs are endemic will contribute to the development of a new generation of scientists who will be better able to understand and manage the challenges of these diseases.
Reducing Stigma and Disabilities
Via this research project we seek to guarantee the Right to Health of people with disabilities, with a special focus on those with NTDs in Côte d’Ivoire and Benin.
A New Clinical Study to Improve the Treatment of Leprosy and Prevent its Harmful Side Effects
Via this study, we will enhance capacity-building, strengthen active integrated case detection, as well as enable early detection and accurate diagnoses.
